<div class="govuk-grid-row">
  <div class="govuk-grid-column-two-thirds">
    <div class="gem-c-title govuk-!-margin-top-8 govuk-!-margin-bottom-8">
    <p class="gem-c-title__context">
      Guidance
    </p>
  <h1 class="gem-c-title__text gem-c-title__text--long">
    Guidance on substantial amendments to a clinical trial if the UK leaves the EU with no deal
  </h1>
</div>
  </div>
  
  <div class="govuk-grid-column-two-thirds">
    
  <p class="gem-c-lead-paragraph ">
    This guidance covers significant amendments to a clinical trial including changes to the trial sponsor/legal representative, Investigational medicinal product (IMP) certification and importation and amendments to the Research Ethics Committee (REC).
  </p>

  </div>
</div>

<div class="govuk-grid-row">
  <div class="metadata-logo-wrapper">
    <div class="govuk-grid-column-two-thirds metadata-column">
        <div class="app-c-publisher-metadata" lang="en">
    <div class="app-c-published-dates " lang="en">
    Published 3 April 2019
    <br></br>Last updated 7 August 2019
      — <a href="#history">see all updates</a>
</div>

      <div class="app-c-publisher-metadata__other">
        <dl data-module="track-click">
            <dt class="app-c-publisher-metadata__term">
              From:
            </dt>
            <dd class="app-c-publisher-metadata__definition" data-module="gem-toggle">
                <span class="app-c-publisher-metadata__definition-sentence">
                  <a href="/government/organisations/medicines-and-healthcare-products-regulatory-agency">Medicines and Healthcare products Regulatory Agency</a>
                </span>
            </dd>
        </dl>
      </div>
  </div>

    </div>
    <div class="govuk-grid-column-one-third">
    </div>
  </div>
</div>




<div class="govuk-grid-row">
  <div class="govuk-grid-column-two-thirds">
    

      <div id="contents" class="app-c-contents-list-with-body" data-module="sticky-element-container">
      <div class="responsive-bottom-margin">
          <nav role="navigation" class="gem-c-contents-list gem-c-contents-list--no-underline " data-module="track-click">
      <h2 class="gem-c-contents-list__title">Contents</h2>

    <ol class="gem-c-contents-list__list">
        <li class="gem-c-contents-list__list-item gem-c-contents-list__list-item--dashed ">
          <a class="gem-c-contents-list__link " data-track-category="contentsClicked" data-track-action="content_item 1" data-track-label="#changes-to-the-trial-sponsor-legal-representative" data-track-options="{"dimension29":"Changes to the trial sponsor/ legal representative"}" href="#changes-to-the-trial-sponsor-legal-representative">Changes to the trial sponsor/ legal representative</a>
        </li>
        <li class="gem-c-contents-list__list-item gem-c-contents-list__list-item--dashed ">
          <a class="gem-c-contents-list__link " data-track-category="contentsClicked" data-track-action="content_item 2" data-track-label="#investigational-medicinal-product-imp-certification-and-importation" data-track-options="{"dimension29":"Investigational medicinal product (IMP) certification and importation"}" href="#investigational-medicinal-product-imp-certification-and-importation">Investigational medicinal product (IMP) certification and importation</a>
        </li>
        <li class="gem-c-contents-list__list-item gem-c-contents-list__list-item--dashed ">
          <a class="gem-c-contents-list__link " data-track-category="contentsClicked" data-track-action="content_item 3" data-track-label="#amendments-relevant-to-the-research-ethics-committee-rec" data-track-options="{"dimension29":"Amendments relevant to the Research Ethics Committee (REC)"}" href="#amendments-relevant-to-the-research-ethics-committee-rec">Amendments relevant to the Research Ethics Committee (REC)</a>
        </li>
    </ol>
  </nav>

      </div>
    
      
<div class="gem-c-govspeak govuk-govspeak direction-ltr" data-module="govspeak">
      <div class="govspeak">
<div class="call-to-action">
<p>Note that any arrangements solely for sites outside the <abbr title="United Kingdom">UK</abbr> that do not affect the approved <abbr title="United Kingdom">UK</abbr> trial do not need to be notified as substantial amendments in the <abbr title="United Kingdom">UK</abbr>.</p>
</div>

<h2 id="changes-to-the-trial-sponsor-legal-representative">Changes to the trial sponsor/ legal representative</h2>

<p>The <abbr title="United Kingdom">UK</abbr> would require the sponsor or legal representative of a clinical trial to be in the <abbr title="United Kingdom">UK</abbr> or country on an approved country list which would initially include <abbr title="European Union">EU</abbr>/European Economic Area (<abbr title="European Economic Area">EEA</abbr>) countries.</p>

<p>A change in sponsor or legal representative for an <abbr title="United Kingdom">UK</abbr> trial is a substantial amendment requiring submission to both <abbr title="Medicines and Healthcare products Regulatory Agency">MHRA</abbr> and the Research Ethics Committee (<abbr title="Research Ethics Committee">REC</abbr>).</p>

<h3 id="action-to-take-if-there-is-a-no-deal-brexit">Action to take if there is a no deal Brexit</h3>

<p>Where the sponsor is from the rest of the world and the legal representative is established in the <abbr title="United Kingdom">UK</abbr> and there are sites elsewhere in the <abbr title="European Union">EU</abbr>/<abbr title="European Economic Area">EEA</abbr>, the sponsor will need to assign an <abbr title="European Union">EU</abbr>/<abbr title="European Economic Area">EEA</abbr> legal representative for these sites.</p>

<p>No amendment is required where the sponsor or legal representative for an ongoing trial is established in the <abbr title="European Union">EU</abbr>/<abbr title="European Economic Area">EEA</abbr> as the <abbr title="United Kingdom">UK</abbr> will continue to accept this.</p>

<p>No amendment will need to be submitted in the <abbr title="United Kingdom">UK</abbr> if the sponsor retains the <abbr title="United Kingdom">UK</abbr> legal representative for the <abbr title="United Kingdom">UK</abbr> study. Similarly, no amendment will need to be submitted in the <abbr title="United Kingdom">UK</abbr> if a sponsor remains in the <abbr title="United Kingdom">UK</abbr> and a legal representative is added to cover <abbr title="European Union">EU</abbr>/<abbr title="European Economic Area">EEA</abbr> sites.</p>

<h2 id="investigational-medicinal-product-imp-certification-and-importation">Investigational medicinal product (<abbr title="Investigational Medicinal Product">IMP</abbr>) certification and importation</h2>

<p>As is the case today, a substantial amendment will be required to be submitted to <abbr title="Medicines and Healthcare products Regulatory Agency">MHRA</abbr> to change (add/replace) any <abbr title="Investigational Medicinal Product">IMP</abbr> manufacturing, importation or certification site relevant for supply of <abbr title="Investigational Medicinal Product">IMP</abbr> to an ongoing <abbr title="United Kingdom">UK</abbr> trial.</p>

<p>If the sponsor chooses to retain an existing <abbr title="United Kingdom">UK</abbr> <abbr title="Investigational Medicinal Product">IMP</abbr> release site for the ongoing <abbr title="United Kingdom">UK</abbr> trial but includes an additional <abbr title="European Union">EU</abbr>/<abbr title="European Economic Area">EEA</abbr> site for trials in the <abbr title="European Union">EU</abbr>/<abbr title="European Economic Area">EEA</abbr> only, then no substantial amendment to <abbr title="Medicines and Healthcare products Regulatory Agency">MHRA</abbr> will be required.</p>

<p>As described in the <a href="https://www.gov.uk/government/publications/further-guidance-note-on-the-regulation-of-medicines-medical-devices-and-clinical-trials-if-theres-no-brexit-deal/further-guidance-note-on-the-regulation-of-medicines-medical-devices-and-clinical-trials-if-theres-no-brexit-deal">further guidance note on the regulation of medicines, medical devices and clinical trials if there’s no Brexit deal</a>, the <abbr title="Investigational Medicinal Product">IMP</abbr> supply chain from a country on the approved country list which would initially include <abbr title="European Union">EU</abbr>/<abbr title="European Economic Area">EEA</abbr> countries, will allow direct supply to clinical investigator sites.</p>

<h3 id="action-to-take-if-there-is-a-no-deal-brexit-1">Action to take if there is a no deal Brexit</h3>

<p>After a transition period of 1 year from the date the <abbr title="United Kingdom">UK</abbr> leaves the <abbr title="European Union">EU</abbr>, this direct supply must be supervised by a Manufacturing and Import Authorisation for Investigational Medicinal Products (<abbr title="Manufacturing and Import Authorisation for Investigational Medicinal Products">MIA(IMP)</abbr>) holder who will be required to put in place an assurance system to check these <abbr title="Investigational Medicinal Products">IMPs</abbr> have been Qualified Person (<abbr title="Qualified Person">QP</abbr>) certified in the <abbr title="European Union">EU</abbr> or <abbr title="European Economic Area">EEA</abbr>. This assurance system must be overseen by a <abbr title="Qualified Person">QP</abbr>.</p>

<p>The holder is required to be included for importation to an ongoing <abbr title="United Kingdom">UK</abbr> trial, a substantial amendment should be submitted to the <abbr title="Medicines and Healthcare products Regulatory Agency">MHRA</abbr> to include the details of the <abbr title="Manufacturing and Import Authorisation for Investigational Medicinal Products">MIA(IMP)</abbr> holder performing the ‘supply chain oversight’ role within 1 year of the <abbr title="United Kingdom">UK</abbr> leaving the <abbr title="European Union">EU</abbr>.</p>

<p>This means that for up to 1 year after the <abbr title="United Kingdom">UK</abbr> leaves the <abbr title="European Union">EU</abbr>, <abbr title="Investigational Medicinal Products">IMPs</abbr> may be supplied direct from the <abbr title="European Economic Area">EEA</abbr> <abbr title="Manufacturing and Import Authorisation for Investigational Medicinal Products">MIA(IMP)</abbr> holder to the <abbr title="United Kingdom">UK</abbr> trial site without the <abbr title="United Kingdom">UK</abbr> <abbr title="Manufacturing and Import Authorisation">MIA</abbr> (<abbr title="Investigational Medicinal Product">IMP</abbr>).</p>

<h2 id="amendments-relevant-to-the-research-ethics-committee-rec">Amendments relevant to the Research Ethics Committee (<abbr title="Research Ethics Committee">REC</abbr>)</h2>

<p>The Health Research Authority (<abbr title="Health Research Authority">HRA</abbr>) has produced <a rel="external" href="https://www.hra.nhs.uk/about-us/news-updates/handling-amendments-no-deal-brexit-hra-guidance/">guidance on when amendments are required to be submitted for <abbr title="Research Ethics Committee">REC</abbr> review</a>.</p>

<p>This guidance will apply from exit day in line with the <a rel="external" href="http://www.legislation.gov.uk/uksi/2019/775/contents/made">Human Medicines Regulations (Amendment etc.) (<abbr title="European Union">EU</abbr> Exit) Regulations 2019</a>.</p>

<div class="call-to-action">
<h3 id="stay-up-to-date">Stay up to date</h3>

<p>This page tells you what to do if you the <abbr title="United Kingdom">UK</abbr> leaves the <abbr title="European Union">EU</abbr> without a deal. It will be updated if anything changes, including if a deal is agreed.</p>

<p><a href="https://www.gov.uk/email-signup/?topic=/government/brexit">Sign up to email alerts</a> to get the latest information</p>
</div>

</div>
</div>


      <div class="responsive-bottom-margin">
        <div class="app-c-published-dates app-c-published-dates--history" id="history" data-module="toggle" lang="en">
    Published 3 April 2019
    <br></br>Last updated 7 August 2019
      <a href="#full-history" class="app-c-published-dates__toggle" data-controls="full-history" data-expanded="false" data-toggled-text="- hide all updates">+ show all updates</a>
      <div class="app-c-published-dates__change-history js-hidden" id="full-history">
        <ol>
            <li class="app-c-published-dates__change-item">
              <time class="app-c-published-dates__change-date timestamp" datetime="2019-08-07T15:34:04.000+01:00">7 August 2019</time>
              We have removed some outdated background information and re-worded some content to focus on the actions clinical trial sponsors will need to take.
            </li>
            <li class="app-c-published-dates__change-item">
              <time class="app-c-published-dates__change-date timestamp" datetime="2019-04-03T13:34:00.000+01:00">3 April 2019</time>
              First published.
            </li>
        </ol>
      </div>
</div>

      </div>

      <div data-sticky-element class="app-c-contents-list-with-body__link-wrapper">
        <div class="app-c-contents-list-with-body__link-container">
          <a class="app-c-back-to-top dont-print" href="#contents">
    <svg class="app-c-back-to-top__icon" xmlns="http://www.w3.org/2000/svg" width="13" height="17" viewbox="0 0 13 17">
      <path fill="currentColor" d="M6.5 0L0 6.5 1.4 8l4-4v12.7h2V4l4.3 4L13 6.4z"></path>
    </svg>
    Contents
</a>

        </div>
      </div>
  </div>
  </div>
  
<div class="govuk-grid-column-one-third">
  
<div class="gem-c-contextual-sidebar">

    
  <div class="gem-c-related-navigation">

      <h2 id="related-nav-related_items-e33089c1" class="gem-c-related-navigation__main-heading" data-track-count="sidebarRelatedItemSection">
        Related content
      </h2>




      <nav role="navigation" class="gem-c-related-navigation__nav-section" aria-labelledby="related-nav-related_items-e33089c1" data-module="gem-toggle">


  <ul class="gem-c-related-navigation__link-list" data-module="track-click">


        <li class="gem-c-related-navigation__link"><a class="gem-c-related-navigation__section-link gem-c-related-navigation__section-link--sidebar  gem-c-related-navigation__section-link--other" data-track-category="relatedLinkClicked" data-track-action="1.1 Related content" data-track-label="/find-eu-exit-guidance-business" data-track-options="{"dimension28":"1","dimension29":"Find Brexit guidance for your business"}" href="/find-eu-exit-guidance-business">Find Brexit guidance for your business</a></li>

  </ul>
</nav>



      <nav role="navigation" class="gem-c-related-navigation__nav-section" aria-labelledby="related-nav-collections-e33089c1" data-module="gem-toggle">

    <h3 id="related-nav-collections-e33089c1" class="gem-c-related-navigation__sub-heading gem-c-related-navigation__sub-heading--sidebar" data-track-count="sidebarRelatedItemSection">Collection</h3>

  <ul class="gem-c-related-navigation__link-list" data-module="track-click">


        <li class="gem-c-related-navigation__link"><a class="gem-c-related-navigation__section-link gem-c-related-navigation__section-link--sidebar" data-track-category="relatedLinkClicked" data-track-action="2.1 Collection" data-track-label="/government/collections/mhra-guidance-and-publications-on-a-possible-no-deal-scenario" data-track-options="{"dimension28":"1","dimension29":"MHRA guidance and publications about a possible no deal Brexit"}" href="/government/collections/mhra-guidance-and-publications-on-a-possible-no-deal-scenario">MHRA guidance and publications about a possible no deal Brexit</a></li>

  </ul>
</nav>

  </div>


</div>

</div>

</div>


  <div class="govuk-grid-row">
    <div class="govuk-grid-column-two-thirds">
        
  <div class="gem-c-contextual-footer">
    
  <div class="gem-c-related-navigation">





      <nav role="navigation" class="gem-c-related-navigation__nav-section" aria-labelledby="related-nav-topics-90daef56" data-module="gem-toggle">

    <h2 id="related-nav-topics-90daef56" class="gem-c-related-navigation__sub-heading gem-c-related-navigation__sub-heading--footer" data-track-count="footerRelatedItemSection">Explore the topic</h2>

  <ul class="gem-c-related-navigation__link-list" data-module="track-click">


        <li class="gem-c-related-navigation__link"><a class="gem-c-related-navigation__section-link gem-c-related-navigation__section-link--footer" data-track-category="relatedLinkClicked" data-track-action="1.1 Explore the topic" data-track-label="/topic/medicines-medical-devices-blood/clinical-trials-investigations" data-track-options="{"dimension28":"2","dimension29":"Clinical trials and investigations"}" href="/topic/medicines-medical-devices-blood/clinical-trials-investigations">Clinical trials and investigations</a></li>
        <li class="gem-c-related-navigation__link"><a class="gem-c-related-navigation__section-link gem-c-related-navigation__section-link--footer" data-track-category="relatedLinkClicked" data-track-action="1.2 Explore the topic" data-track-label="/topic/medicines-medical-devices-blood/manufacturing-wholesaling-importing-exporting-medicines" data-track-options="{"dimension28":"2","dimension29":"Manufacturing, wholesaling, importing and exporting medicines"}" href="/topic/medicines-medical-devices-blood/manufacturing-wholesaling-importing-exporting-medicines">Manufacturing, wholesaling, importing and exporting medicines</a></li>

  </ul>
</nav>

  </div>

  </div>


    </div>
  </div>